A Phase Ib Clinical Trial to Investigate the Safety, Tolerability, Preliminary Efficacy, and Pharmacokinetic Profile of AC-003 Capsules in Patients With Acute GraftVersus-Host Disease (aGVHD)
Latest Information Update: 07 Apr 2026
At a glance
- Drugs AC 003 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Accropeutics
Most Recent Events
- 16 Mar 2026 Planned primary completion date changed from 31 Dec 2025 to 30 Sep 2026.
- 05 Mar 2025 New trial record